Armistice Capital, LLC Increases Stake in Aethlon Medical, Inc. to 4.99%

On May 15, 2026, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G (Amendment No. 1) regarding their holdings in Aethlon Medical, Inc. (AEMD). The filing reports that as of March 31, 2026, the reporting persons beneficially own 82,410 shares of common stock, representing a 4.99% ownership stake in the company. This reflects an increase from a previously reported 0.0% position. Armistice Capital, LLC serves as the investment manager to the Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to have beneficial ownership. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Consequently, the reporting persons have certified that their ownership has fallen to or below the 5% threshold, as noted in Item 5 of the filing.